Definitive Contract HHSN272201500030C
Award Date
9/14/15
Potential Completion Date
9/14/19
Potential Value
$1.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
PAI Life Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $210,507.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business, for the "AEROSOLIZED DELIVERY OF ANTI-TUBERCULAR DRUGS" project. The contract is a Definitive Contract with a Firm Fixed Price pricing type. PAI Life Sciences will be the prime contractor, and Research Triangle Institute (RTI International), a non-profit research organization, will...
The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,946 Small Business Innovation Research (SBIR) Phase I contract to Aerophase, Inc., a self-certified small disadvantaged business, for the "Treatment of Tuberculosis with Inhaled Delivery of Clofazimine." The contract is a firm-fixed-price definitive contract with a completion date of July 31, 2016. This contract supports research and development of an...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Northbound Therapeutics, Inc., a minority-owned, woman-owned small business, to develop an inhaled clofazimine powder as a novel treatment for multidrug-resistant tuberculosis (MDR-TB). The contract, valued at $37,500, is for the formulation and preclinical evaluation of the inhaled clofazimine powder. This SBIR contract is a Firm Fixed Price...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The award, valued at $1,100,191, is a task order under the Nonclinical Services for Development of Interventional Agents Indefinite Delivery, Indefinite Quantity (IDIQ) contract held by the prime contractor, Research Triangle Institute (RTI International). RTI International is a non-profit research organization that...
This is a purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the National Institute For Research In Tuberculosis, a non-profit organization that operates as a hospital. The $537,500.00 firm fixed price award is to provide support to conduct studies on tuberculosis in India. The contract has a performance period ending on May 31, 2019 and was awarded on November 30, 2015. No set-aside was used for this contract. The National...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $110,000.00 firm fixed price purchase order to the National Institute for Research in Tuberculosis in India. The order is for unspecified "other functions" related to tuberculosis research. The award does not have a set-aside designation and was completed on January 27, 2014. The National Institute for Research in Tuberculosis is an international non-profit organization that has previously participated...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded PAI Life Sciences Inc. a $597,953 definitive contract to develop late stage adjuvant mimics based on toll-like receptor 4 agonists. As a self-certified small disadvantaged business, this contract was designated as a total small business set aside. PAI Life Sciences will provide products and services to the National Institute of Allergy and Infectious Diseases in support of their program for late stage...
This federal contract award was made by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Creare LLC, doing business as Creare, a small business engineering research and development company. The $591,870.00 Small Business Innovation Research (SBIR) Phase I contract is for the development of an optimized dry powder formulation and delivery system for the anti-tuberculosis drug clofazimine. The...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The $2,338,680.13 definitive contract is for the Phase II development of a prophylactic onchocerciasis (river blindness) vaccine under the SBIR program. The contract is a cost plus fixed fee arrangement with a completion date of May 15, 2024. PAI Life Sciences is collaborating with Thomas...
This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...